Forbes rich list released… #1 to be assassinated?

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

David Michael Johnson net worth and biography

David Johnson Biography and Net Worth

Director of Zentalis Pharmaceuticals

Dave Johnson has more than 25 years of experience in the biopharmaceutical industry, spanning pre-clinical through all phases of clinical development, regulatory approval and product launch. He is currently the CEO of VelosBio, a clinical-stage, oncology focused, venture backed biopharmaceutical company advancing novel antibody-drug-conjugate and bispecific antibody technologies. From 2013 to 2016, he was with Acerta Pharma, an oncology focused pharmaceutical company, where he rose to Chief Executive Officer leading the company through the required growth to advance acalabrutinib from early to late-stage global clinical development. His tenure at Acerta culminated in the execution of a strategic transaction with AstraZeneca valued at up to $7 billion.

He has held positions of increasing responsibility at Calistoga (acq. by Gilead), Gloucester (acq. by Celgene), Favrille, Millennium (acq. by Takeda), Immunex (acq. by Amgen), and Hoffman-La Roche. Dave is a co-author on numerous publications, including three NEJM publications, and has a bachelor’s degree from Indiana University.

What is David Michael Johnson's net worth?: The estimated net worth of David Michael Johnson is at least $431,723.11 as of November 10th, 2023. Mr. Johnson owns 144,389 shares of Zentalis Pharmaceuticals stock worth more than $431,723 as of December 18th. This net worth evaluation does not reflect any other assets that Mr. Johnson may own. Learn More about David Michael Johnson's net worth.
How do I contact David Michael Johnson?: The corporate mailing address for Mr. Johnson and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on David Michael Johnson's contact information.
Has David Michael Johnson been buying or selling shares of Zentalis Pharmaceuticals?: David Michael Johnson has not been actively trading shares of Zentalis Pharmaceuticals during the last quarter. Most recently, on Friday, November 10th, David Michael Johnson bought 17,000 shares of Zentalis Pharmaceuticals stock. The stock was acquired at an average cost of $9.88 per share, with a total value of $167,960.00. Following the completion of the transaction, the director now directly owns 144,389 shares of the company's stock, valued at $1,426,563.32. Learn More on David Michael Johnson's trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 18,302 shares worth more than $205,276.56. The most recent insider tranaction occured on October, 4th when insider Vincent Vultaggio sold 1,603 shares worth more than $5,097.54. Insiders at Zentalis Pharmaceuticals own 3.6% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 10/4/2024.

David Michael Johnson Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/10/2023	Buy	17,000	$9.88	$167,960.00	144,389
10/4/2021	Sell	12,896	$66.35	$855,649.60
4/5/2021	Sell	12,897	$43.50	$561,019.50	88,855
12/2/2020	Sell	12,896	$51.39	$662,725.44	114,648
4/7/2020	Buy	4,000	$18.00	$72,000.00	114,648

David Michael Johnson Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $2.99

$2.97

$3.22

50 Day Range

MA: $3.33

$2.70

$4.03

2 Week Range

Now: $2.99

$2.66

$18.07

Volume

442,280 shs

Average Volume

1,301,496 shs

Market Capitalization

$213.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84